title: Exposure of procoagulant phospholipids on the surface of platelets in patients undergoing cardiopulmonary bypass using non-coated and heparin-coated extracorporeal circuits.
abstract: Cardiopulmonary bypass (CPB) is associated with a generalized hemostatic defect, in which platelet dysfunction seems to play a central role. The present study was designed to elucidate whether the potential procoagulant activity of platelets, detected as annexin V binding, was altered during coronary bypass surgery, using non-coated and heparin-coated extracorporeal circuits. Thirty patients undergoing elective coronary artery bypass grafting were prospectively randomized using either a standard untreated extracorporeal circuit (n = 15) or a heparin-treated extracorporeal circuit (n=15). Besides measurement of the procoagulant phospholipid activity, the mediastinal blood loss after surgery, and the blood transfusion requirements were also monitored. CPB induced a decrease in the percentage of activated platelets in whole blood, manifest directly after start of CPB, which was significantly attenuated using a non-treated system. Postoperatively, the percentage of activated platelets recovered in both systems, reaching a point of significance 24 hours after the operation, compared to the values 2 hours after the operation. The differences among the groups for mediastinal blood loss during the first 2 and 24 postoperative hours coincided with the differences in procoagulant phospholipid activity. Furthermore, there was no statistical difference among the groups for blood transfusion requirements. The platelets in both groups showed a significantly lower ability to generate ionomycin-induced procoagulant activity after blood-material interaction when compared to the baseline values. These observations are compatible with the notion that during CPB, irrespective of the heparin coating, platelets become modestly activated.
authors.affiliation: Department of Extracorporeal Circulation, University Medical Center Nijmegen, The Netherlands. P.Weerwind@thorax.umcn.nl
authors.forename: P W
authors.initials: PW
authors.lastname: Weerwind
authors.forename: N E H
authors.initials: NE
authors.lastname: Caberg
authors.forename: C P M
authors.initials: CP
authors.lastname: Reutelingsperger
authors.forename: T
authors.initials: T
authors.lastname: Lindhout
authors.forename: D S
authors.initials: DS
authors.lastname: de Jong
mesh_terms: D000368:Aged; D017304:Annexin A5 / Q000378:metabolism*; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D001026:Coronary Artery Bypass; D005112:Extracorporeal Circulation / Q000295:instrumentation / Q000379:methods*; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D015759:Ionomycin / Q000494:pharmacology*; D007476:Ionophores / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects*; D011183:Postoperative Complications
chemical_list: D017304:Annexin A5; D007476:Ionophores; D015759:Ionomycin; D006493:Heparin